(Q80977096)
Statements
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies (English)
Maryalice Stetler-Stevenson
Wyndham H Wilson
Robert J Kreitman
David R Squires
Pierre Noel
David J P FitzGerald